1、教育经历
(1) 2004/09-2012/02, 中国药科大学,药学院,博士
(2) 1999/09-2003/07, 中国药科大学,药学院,硕士
2、工作经历
(1) 2020/07 至今,   中国药科大学,药学院,教授
(2) 2005/06-2020/07, 中国药科大学, 药学院,副教授
            (1) 基于人工智能的先导化合物发现
(2) 基于计算机辅助药物设计的先导化合物发现
(3) 针对重大疾病的创新药物的发现
            1、科研项目
(1)科技部, 国家重点研发计划重大专项项目,2018YFC0311004,海洋微生物先导物的规模化制备及关键技术研究,2018-08 至 2021-12,37.33万元,已结题,子课题负责人
(2)国家自然科学基金委员会,面上项目,81573348,RpsA作为抗耐药结核杆菌药靶有效性确认及活性化合物发现,2016-01-01 至 2019-12-30,68万元,已结题,主持
            1.Huang, B.;  Bai, Z.;  Ye, X.;  Zhou, C.;  Xie, X.;  Zhong, Y.;  Lin, K.; Ma, L., Structural analysis and binding sites of inhibitors targeting the CD47/SIRPα interaction in anticancer therapy. Computational and Structural Biotechnology Journal 2021, 19, 5494-5503. IF: 7.271
2.Shan, W.;  Li, X.;  Yao, H.; Lin, K., Convolutional Neural Network based Virtual Screening. Curr. Med. Chem. 2021, 28 (10), 2033-2047. IF: 4.503
3.Li, X.;  Ding, Z.;  Wu, Z.;  Xu, Y.;  Yao, H.; Lin, K., Targeting the TGF-beta signaling pathway for fibrosis therapy: a patent review (2015-2020). Expert Opin Ther Pat 2021, 31 (8), 723. IF: 6.674
4.Zhang, T.;  Huang, F.;  Li, B.;  Huang, C.;  Xu, C.;  Lin, K.; Lin, D., NMR-based metabolomic analysis for the effects of Huiyang Shengji extract on rat diabetic skin ulcers. J. Ethnopharmacol. 2020, 261, 112978. IF:4.360
5.Yi, S.;  Lin, K.;  Jiang, T.;  Shao, W.;  Huang, C.;  Jiang, B.;  Li, Q.; Lin, D., NMR-based metabonomic analysis of HUVEC cells during replicative senescence. Aging (Albany NY) 2020, 12 (4), 3626-3646. IF: 4.831
6.Li, X.;  Xu, Y.;  Yao, H.; Lin, K., Chemical Space Exploration Based on Recurrent Neural Networks: Applications in Discovering Kinase Inhibitors. Journal of Cheminformatics 2020, 12 (42), 1-13. IF: 5.514
7.1. Dai, Y.;  Xu, Y.;  Guo, C.;  Xue, X.;  Lin, D.; Lin, K., Discovery and evaluation of new compounds targeting ribosomal protein S1 in antibiotic-resistant Mycobacterium Tuberculosis. Eur. J. Med. Chem. 2020, 196, 112317. IF: 6.514
8.Chen, P.;  Xu, Y.;  Li, X.;  Yao, H.; Lin, K., Development and strategies of CDK4/6 inhibitors. Future Med Chem 2020, 12 (2), 127-145. IF:3.808
9. Zhong, Y.;  Li, X.;  Zhu, D.;  Zhao, N.;  Yao, H.; Lin, K., Characteristics of parathyroid hormone-1 receptor agonists and antagonists. Future Medicinal Chemistry 2019, 11 (8), 817-831. IF: 3.609
10.Zhong, Y.;  Li, X.;  Yao, H.; Lin, K., The Characteristics of PD-L1 Inhibitors, from Peptides to Small Molecules. Molecules 2019, 24 (10), 1940. IF: 3.351
11.Zhi, Y.;  Dai, Y.;  Yang, J.;  Tan, S.;  Lin, D.; Lin, K., Lead compounds and key residues of ribosomal protein S1 in drug-resistant Mycobacterium tuberculosis. Bioorg. Chem. 2019, 82, 58-67. IF: 4.831
Xu, Y.;  Chen, P.;  Lin, X.;  Yao, H.; Lin, K., Discovery of CDK4 inhibitors by convolutional neural networks. Future Medicinal Chemistry 2019, 11 (3), 165-177. 
            
        
			
